Key Points

• Hims & Hers reported accelerating domestic revenue growth and international expansion, while raising its 2026 revenue outlook.
• Management reiterated 2030 targets of at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA.
• The broader industry outlook includes developments at Precision Peptide, Novo Nordisk, Eli Lilly and Enhanced.
• Grand View Research forecasts that the global peptide therapeutics market could reach $294.6 billion by 2033.
• The companies represent different businesses and development stages; their updates are not equally direct evidence of peptide-related growth.

Hims & Hers Health (NYSE: HIMS) said its platform serves nearly 3 million people, with second-quarter 2026 domestic revenue growth accelerating to 16% year over year.

International revenue grew more than 17-fold, strengthened by the June completion of its Eucalyptus acquisition. That acquisition contribution is important context: the reported international increase should not be treated as entirely organic growth.

Hims & Hers Raises Outlook and Emphasizes AI Investment

Management raised its 2026 revenue outlook, although the supplied information does not include the revised range. It also expressed greater confidence in its 2030 targets of:

• At least $6.5 billion in revenue.
• $1.3 billion in adjusted EBITDA.

The company highlighted a doctor-led AI clinical engine and technology investments intended to improve efficiency, affordability and access to personalized care.

These are company-wide developments. The supplied figures do not isolate peptide-related revenue, GLP-1 patient growth or the contribution of particular treatments.

Precision Peptide Expands Its Telehealth Formulary

The Precision Peptide Company (OTCQB: PNGAF) expanded its U.S. prescription formulary from four to 16 therapies in less than four months.

Its offering now spans seven areas: weight management, performance and growth hormone support, recovery, longevity and cellular health, immune support, cognitive health, and sexual wellness.

The company also introduced clinician-tailored, multi-therapy programs. The portfolio includes its BPC-157 Recovery Patch and six oral and topical formulations, for a total of 23 products.

According to the company, a U.S.-licensed clinician reviews prescriptions, and a licensed U.S. 503A pharmacy compounds them. The portfolio expansion does not, by itself, establish clinical benefits or commercial profitability.

Novo Nordisk Reports CagriSema Findings in Women

Novo Nordisk (NYSE: NVO) presented two post hoc analyses of its REDEFINE 1 trial involving investigational CagriSema, a combination of cagrilintide and semaglutide.

In an analysis of 2,309 women with overweight or obesity, average weight loss at Week 68 was 25.0% with CagriSema versus 3.0% with placebo under an analysis assuming treatment adherence.

A separate analysis reported weight loss across premenopausal, perimenopausal and postmenopausal groups. Because these were post hoc analyses, they should be distinguished from prospectively designed trials specifically testing differences by menopausal status.

Eli Lilly Reports Positive Head-to-Head Phase 3 Results

Eli Lilly (NYSE: LLY) reported that retatrutide met the primary and all key secondary endpoints in TRANSCEND-T2D-2, an 80-week Phase 3 trial in adults with type 2 diabetes.

According to the supplied information, retatrutide produced greater A1C reduction and weight loss than injectable Ozempic 2 mg. Numerical treatment differences and detailed safety findings were not included, limiting assessment of the magnitude and overall benefit-risk comparison.

Investor Takeaway: Separate Industry Growth From Company Execution

The supplied article cites Grand View Research forecasts that peptide therapeutics could grow from approximately $140.9 billion in 2025 to $294.6 billion by 2033. A separate peptide synthesis forecast projects growth from approximately $961 million in 2024 to $1.84 billion by 2033.

For HIMS investors, the more concrete developments are accelerating domestic growth, acquisition-supported international expansion and the raised annual outlook. Those operating measures provide a clearer basis for evaluating the business than the industry forecast alone.

Across all five companies, the relevant milestones differ: commercial execution at Hims & Hers and Precision Peptide, clinical development at Novo Nordisk and Lilly, and brand development at Enhanced. A shared market narrative does not make their opportunities, or risks, equivalent.

The post Hims & Hers Highlights Growth as Peptide Market Forecast Approaches $295 Billion appeared first on PRISM MarketView.

COMTEX_1001978333/2927/2026-10-29T15:31:21